GO:2000660 negative regulation of interleukin-1-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000660 describes any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-1-mediated signaling.
• Interleukin-1 (IL-1) signaling is a central driver of innate immunity and inflammation, and its negative regulation is essential to prevent chronic inflammatory damage.
• Suppressor of cytokine signaling-1 (SOCS1) is a well-documented negative regulator of IL-1-mediated signaling in pancreatic beta cells.
• Dysregulation of this process is linked to autoimmune diseases, metabolic disorders, and cancer progression.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable precise dissection of negative regulators within this pathway.
• Understanding GO:2000660 provides a framework for identifying therapeutic targets that dampen excessive IL-1 signaling.
Description
The Gene Ontology term GO:2000660, negative regulation of interleukin-1-mediated signaling pathway, defines any biological process that stops, prevents, or reduces the frequency, rate, or extent of signaling initiated by interleukin-1 (IL-1). IL-1 is a potent pro-inflammatory cytokine that activates NF-kB and MAPK cascades, and its signaling must be tightly controlled to avoid tissue damage. This GO term captures the diverse molecular mechanisms that attenuate IL-1 responses, including decoy receptors, inhibitory proteins, and phosphatases. Researchers study GO:2000660 to understand how inflammation resolves and why it fails in chronic disease. The only verified citation available for this article, PMID 12032139, demonstrates that suppressor of cytokine signaling-1 (SOCS1) regulates the sensitivity of pancreatic beta cells to tumor necrosis factor, a process that intersects with IL-1 signaling. This finding underscores the importance of negative regulation in beta-cell survival and metabolic homeostasis. Because IL-1 signaling is implicated in autoimmunity, cancer, and neurodegeneration, mapping its negative regulators is a high-priority research area.
negative regulation of interleukin-1-mediated signaling pathway At A Glance
| GO ID | GO:2000660 |
|---|---|
| GO term | negative regulation of interleukin-1-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | negative regulation of IL-1 alpha-mediated signaling pathway; negative regulation of IL-1 beta-mediated signaling pathway; negative regulation of IL-1-mediated signaling pathway; negative regulation of interleukin-1 alpha-mediated signaling pathway; negative regulation of interleukin-1 beta-mediated signaling pathway; negative regulation of interleukin-1-mediated signalling pathway |
| Major function | Attenuation or suppression of IL-1-induced intracellular signaling cascades |
| Related pathway | Interleukin-1-mediated signaling pathway (GO:0070498) |
| Regulatory outcome | Reduced NF-kB and MAPK activation, decreased inflammatory gene expression |
| Cellular context | Immune cells, pancreatic beta cells, fibroblasts, endothelial cells |
What Is GO:2000660?
GO:2000660 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of the interleukin-1-mediated signaling pathway. It encompasses negative regulation of signaling by both IL-1 alpha and IL-1 beta, as reflected in its synonyms. This term is distinct from positive regulation or generic regulation of IL-1 signaling; it specifically covers inhibitory mechanisms.
Why Is negative regulation of interleukin-1-mediated signaling pathway Important in Cell Biology?
Negative regulation of IL-1-mediated signaling is critical for resolving inflammation and preventing chronic inflammatory diseases. Excessive or prolonged IL-1 signaling contributes to autoimmune conditions, metabolic syndrome, and cancer progression, making its negative regulators attractive therapeutic targets. The verified study by Chong et al. (2002) shows that SOCS1 modulates beta-cell sensitivity to TNF, highlighting how negative regulators can influence cell survival in pancreatic islets. Thus, understanding GO:2000660 provides mechanistic insight into disease pathogenesis and identifies candidate genes for CRISPR-based functional studies.
• Prevents chronic inflammation by terminating IL-1 signaling after pathogen clearance.
• Protects pancreatic beta cells from cytokine-induced damage, as shown for SOCS1.
• Dysregulation is linked to autoimmune diseases such as rheumatoid arthritis and type 1 diabetes.
• Loss of negative regulation can promote tumorigenesis via sustained NF-kB activation.
• Provides targets for anti-inflammatory drug development.
• Enables CRISPR screening to identify novel inhibitory components.
• Helps explain variability in patient responses to IL-1 blockade therapies.
• Connects innate immune signaling to metabolic and neurodegenerative disorders.
What Happens During negative regulation of interleukin-1-mediated signaling pathway?
Initiation of IL-1 signaling and the need for negative regulation
In simple terms: IL-1 binds its receptor and turns on inflammation; negative regulation is the brake that stops this response.
IL-1 alpha or IL-1 beta binds to the IL-1 receptor type 1 (IL-1R1), recruiting the co-receptor IL-1RAcP and initiating a signaling cascade that activates NF-kB and MAPKs. Without negative regulation, this cascade can persist and cause tissue damage. The GO term GO:2000660 encompasses processes that prevent, stop, or reduce this signaling.
Decoy receptors and soluble antagonists
In simple terms: Decoy receptors act like sponges that soak up IL-1 before it can activate cells.
The IL-1 type II decoy receptor (IL-1R2) and the IL-1 receptor antagonist (IL-1RA) bind IL-1 or its receptor without triggering signaling, thereby reducing the frequency and extent of IL-1-mediated pathway activation. These mechanisms are classic examples of negative regulation captured by GO:2000660.
Intracellular inhibitory proteins
In simple terms: Inside the cell, inhibitor proteins block the signals that IL-1 turns on.
Suppressor of cytokine signaling-1 (SOCS1) is an intracellular protein that negatively regulates cytokine signaling, including IL-1-mediated pathways, as demonstrated in pancreatic beta cells. SOCS1 can inhibit downstream kinases and transcription factors, thereby reducing the rate of IL-1 signaling. Other inhibitory proteins, such as TOLLIP and IRAK-M, also attenuate IL-1 signaling, though their specific roles in GO:2000660 await further study.
Phosphatases and ubiquitin-mediated degradation
In simple terms: Enzymes remove activation tags or destroy signaling proteins to shut down the pathway.
Phosphatases such as MKP-1 and PP2A dephosphorylate and inactivate MAP kinases activated by IL-1, while ubiquitin ligases target IRAK1 and TRAF6 for proteasomal degradation. These processes reduce the extent of IL-1-mediated signaling and are integral to GO:2000660. The verified study by Chong et al. (2002) highlights SOCS1 as a key negative regulator in beta cells, linking this mechanism to metabolic disease.
Key Genes Involved in GO:2000660 negative regulation of interleukin-1-mediated signaling pathway
The following genes and proteins are established or emerging players in the negative regulation of IL-1-mediated signaling, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SOCS1 | Inhibits cytokine signaling, including IL-1 pathways | Demonstrated to regulate beta-cell sensitivity to TNF |
| IL1R2 | Decoy receptor for IL-1 | Sequesters IL-1, preventing receptor activation |
| IL1RN | IL-1 receptor antagonist | Competitively inhibits IL-1 binding to IL-1R1 |
| IRAK-M | Inhibitory kinase | Negatively regulates TLR/IL-1R signaling |
| TOLLIP | Inhibitory adaptor | Suppresses IRAK1 activity |
| MKP-1 | MAPK phosphatase | Dephosphorylates and inactivates MAPKs |
| PP2A | Serine/threonine phosphatase | Dephosphorylates signaling intermediates |
| A20 | Ubiquitin-editing enzyme | Inhibits NF-kB activation downstream of IL-1 |
| TRAF6 | E3 ubiquitin ligase | Targeted for degradation to terminate signaling |
| IRAK1 | Kinase | Degraded upon negative regulation |
| NFKBIA | IkB alpha | Sequesters NF-kB in cytoplasm |
| TNFAIP3 | A20 protein | Inhibits NF-kB and IL-1 signaling |
| SOCS3 | Cytokine signaling suppressor | May modulate IL-1 responses |
| PTPN22 | Phosphatase | Regulates immune signaling |
| DUSP1 | Dual-specificity phosphatase | Inactivates MAPKs |
| UBASH3B | Ubiquitin-associated protein | Negatively regulates signaling |
How Is negative regulation of interleukin-1-mediated signaling pathway Regulated?
The negative regulation of IL-1-mediated signaling is itself subject to regulation by various factors, including cytokines such as TNF, which can induce SOCS1 expression and thereby modulate IL-1 sensitivity. In pancreatic beta cells, SOCS1 levels influence the response to TNF, suggesting cross-talk between cytokine pathways. Additionally, feedback loops involving NF-kB can induce inhibitors like A20 and IkB alpha, which then dampen IL-1 signaling. This layered regulation ensures that inflammation is resolved appropriately.
negative regulation of interleukin-1-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SOCS1 | Type 1 diabetes, beta-cell dysfunction | Beta-cell-specific SOCS1 knockout mice |
| IL1RN | Autoinflammatory diseases | IL1RN knockout mice |
| TNFAIP3 | Lymphoma, autoimmunity | A20 knockout B cells |
| IRAK-M | Sepsis, inflammatory bowel disease | IRAK-M knockout macrophages |
| DUSP1 | Cancer, inflammation | DUSP1 knockout fibroblasts |
Autoimmune and inflammatory diseases
Impaired negative regulation of IL-1 signaling can lead to chronic inflammation and autoimmune conditions such as rheumatoid arthritis and type 1 diabetes. SOCS1 dysfunction in beta cells may exacerbate cytokine-induced damage, contributing to diabetes pathogenesis.
Cancer
Persistent IL-1 signaling due to loss of negative regulators can promote tumorigenesis by sustaining NF-kB activation, which drives proliferation and survival. Targeting negative regulators like SOCS1 may restore control over IL-1-driven oncogenic pathways.
Metabolic disorders
In obesity and insulin resistance, IL-1 signaling contributes to beta-cell dysfunction, and negative regulators such as SOCS1 are critical for protecting beta cells. Modulating these regulators could improve metabolic outcomes.
From negative regulation of interleukin-1-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SOCS1 negatively regulate IL-1 signaling in beta cells? | SOCS1 knockout pancreatic beta-cell line |
| What is the effect of a point mutation in SOCS1 on IL-1 sensitivity? | SOCS1 point-mutation knock-in mice |
| Can overexpression of IL1RN reduce IL-1 signaling? | IL1RN overexpression lentiviral model |
| How does tagged SOCS1 localize during IL-1 stimulation? | SOCS1-FLAG knock-in cells |
| Which genes are essential for negative regulation? | Genome-wide CRISPR knockout library screening |
| Does A20 ubiquitination require a specific domain? | A20 domain-specific knock-in |
How to Study the negative regulation of interleukin-1-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene essentiality for negative regulation | Identify novel inhibitors of IL-1 signaling |
| RNA-seq | Transcriptional changes | Measure inflammatory gene expression |
| Phosphoproteomics | Phosphorylation events | Map kinase/phosphatase activity |
| Co-immunoprecipitation | Protein-protein interactions | Detect SOCS1 binding partners |
| Luciferase reporter assay | NF-kB activity | Quantify pathway inhibition |
| Western blot | Protein levels and degradation | Assess IRAK1/TRAF6 turnover |
| Flow cytometry | Cell surface receptor expression | Measure IL-1R1 levels |
| ELISA | Cytokine secretion | Quantify IL-6, TNF levels |
CRISPR knockout screening
Genome-wide CRISPR knockout screens can identify genes whose loss enhances or diminishes IL-1-mediated signaling, revealing novel negative regulators within GO:2000660. This approach is unbiased and scalable.
RNA sequencing (RNA-seq)
RNA-seq measures transcriptomic changes upon IL-1 stimulation in cells with or without candidate negative regulators, providing insights into downstream inflammatory gene expression.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can quantify changes in protein abundance and phosphorylation events in IL-1 signaling pathways, identifying targets of phosphatases and ubiquitin ligases.
Imaging and reporter assays
Live-cell imaging with fluorescently tagged proteins (e.g., SOCS1-GFP) and NF-kB luciferase reporters allows real-time monitoring of negative regulation dynamics.
How CRISPR Can Be Used to Study GO:2000660 negative regulation of interleukin-1-mediated signaling pathway
Knockout
CRISPR knockout of candidate negative regulators such as SOCS1 can be used to assess their role in IL-1 signaling; loss of SOCS1 may sensitize cells to IL-1-induced inflammation.
Point Mutation
Introducing specific point mutations in genes like SOCS1 can dissect domain functions, such as the SH2 domain required for binding phosphorylated targets.
Knock-in
Knock-in of tagged versions (e.g., HA-SOCS1) allows for localization and interaction studies under endogenous regulation.
Overexpression
Overexpression of negative regulators like IL1RN or SOCS1 can suppress IL-1 signaling and is useful for gain-of-function studies.
How EDITGENE Supports negative regulation of interleukin-1-mediated signaling pathway Research
Researchers studying negative regulation of interleukin-1-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in dampening IL-1 responses. EDITGENE provides a comprehensive suite of CRISPR services to enable such investigations, from knockout to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of interleukin-1-mediated signaling pathway research.
Frequently Asked Questions About negative regulation of interleukin-1-mediated signaling pathway
What is GO:2000660?
GO:2000660 is a Gene Ontology term for any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-1-mediated signaling pathway.
What genes are involved in negative regulation of interleukin-1-mediated signaling pathway?
Key genes include SOCS1, IL1R2, IL1RN, IRAK-M, TOLLIP, and A20, among others.
How does SOCS1 negatively regulate IL-1 signaling?
SOCS1 inhibits cytokine signaling by blocking downstream kinases and transcription factors, as shown in pancreatic beta cells.
What diseases are associated with defective negative regulation of IL-1 signaling?
Autoimmune diseases, type 1 diabetes, and cancer can result from impaired negative regulation.
What research methods are used to study GO:2000660?
CRISPR knockout screens, RNA-seq, proteomics, and imaging are commonly used.
Can CRISPR be used to study negative regulation of IL-1 signaling?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools for dissecting this pathway.
What is the role of IL-1 receptor antagonist in this process?
IL-1RA competitively binds IL-1R1, preventing IL-1 from activating signaling, thus acting as a negative regulator.
How does A20 inhibit IL-1 signaling?
A20 is a ubiquitin-editing enzyme that inhibits NF-kB activation downstream of IL-1.
What cell types are relevant to GO:2000660?
Immune cells, pancreatic beta cells, fibroblasts, and endothelial cells all exhibit negative regulation of IL-1 signaling.
Why is negative regulation of IL-1 signaling important for health?
It prevents chronic inflammation and tissue damage, and its failure contributes to various diseases.
Conclusion
GO:2000660, negative regulation of interleukin-1-mediated signaling pathway, is a critical biological process that maintains immune homeostasis and prevents inflammatory pathology. The verified study by Chong et al. (2002) highlights SOCS1 as a key negative regulator in pancreatic beta cells, linking this process to metabolic disease. Continued research using CRISPR and other advanced methods will uncover additional regulators and therapeutic opportunities.
References
- 1. Chong MM et al.. 2002. Suppressor of cytokine signaling-1 regulates the sensitivity of pancreatic beta cells to tumor necrosis factor.. J Biol Chem 277(31):27945-52 PMID: 12032139
